Creo Medical Group Statistics
Total Valuation
AIM:CREO has a market cap or net worth of GBP 45.28 million. The enterprise value is 28.98 million.
Market Cap | 45.28M |
Enterprise Value | 28.98M |
Important Dates
The next estimated earnings date is Tuesday, December 23, 2025.
Earnings Date | Dec 23, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
AIM:CREO has 402.47 million shares outstanding. The number of shares has increased by 17.86% in one year.
Current Share Class | 402.47M |
Shares Outstanding | 402.47M |
Shares Change (YoY) | +17.86% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 3.58% |
Owned by Institutions (%) | 84.82% |
Float | 364.56M |
Valuation Ratios
The trailing PE ratio is 51.02.
PE Ratio | 51.02 |
Forward PE | n/a |
PS Ratio | 9.84 |
PB Ratio | 0.74 |
P/TBV Ratio | 0.75 |
P/FCF Ratio | 6.47 |
P/OCF Ratio | 6.66 |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | 57.96 |
EV / Sales | 6.30 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | 4.14 |
Financial Position
The company has a current ratio of 5.28, with a Debt / Equity ratio of 0.07.
Current Ratio | 5.28 |
Quick Ratio | 4.47 |
Debt / Equity | 0.07 |
Debt / EBITDA | n/a |
Debt / FCF | 0.60 |
Interest Coverage | -57.50 |
Financial Efficiency
Return on equity (ROE) is 4.80% and return on invested capital (ROIC) is -22.69%.
Return on Equity (ROE) | 4.80% |
Return on Assets (ROA) | -20.82% |
Return on Invested Capital (ROIC) | -22.69% |
Return on Capital Employed (ROCE) | -36.62% |
Revenue Per Employee | 35,659 |
Profits Per Employee | 3,876 |
Employee Count | 129 |
Asset Turnover | 0.07 |
Inventory Turnover | 0.43 |
Taxes
Income Tax | -700,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.44% in the last 52 weeks. The beta is 0.55, so AIM:CREO's price volatility has been lower than the market average.
Beta (5Y) | 0.55 |
52-Week Price Change | -49.44% |
50-Day Moving Average | 12.66 |
200-Day Moving Average | 13.84 |
Relative Strength Index (RSI) | 28.38 |
Average Volume (20 Days) | 984,088 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AIM:CREO had revenue of GBP 4.60 million and earned 500,000 in profits.
Revenue | 4.60M |
Gross Profit | 2.10M |
Operating Income | -23.00M |
Pretax Income | 1.90M |
Net Income | 500,000 |
EBITDA | -23.30M |
EBIT | -23.00M |
Earnings Per Share (EPS) | -0.00 |
Balance Sheet
The company has 20.50 million in cash and 4.20 million in debt, giving a net cash position of 16.30 million or 0.04 per share.
Cash & Cash Equivalents | 20.50M |
Total Debt | 4.20M |
Net Cash | 16.30M |
Net Cash Per Share | 0.04 |
Equity (Book Value) | 60.90M |
Book Value Per Share | 0.15 |
Working Capital | 25.70M |
Cash Flow
In the last 12 months, operating cash flow was 6.80 million and capital expenditures 200,000, giving a free cash flow of 7.00 million.
Operating Cash Flow | 6.80M |
Capital Expenditures | 200,000 |
Free Cash Flow | 7.00M |
FCF Per Share | 0.02 |
Margins
Gross margin is 45.65%, with operating and profit margins of -500.00% and 10.87%.
Gross Margin | 45.65% |
Operating Margin | -500.00% |
Pretax Margin | 41.30% |
Profit Margin | 10.87% |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | 152.17% |
Dividends & Yields
AIM:CREO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -17.86% |
Shareholder Yield | n/a |
Earnings Yield | 1.10% |
FCF Yield | 15.46% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
AIM:CREO has an Altman Z-Score of 1.76 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.76 |
Piotroski F-Score | 6 |